Prof. Xinan Sheng 盛锡楠
Chief Physician, Professor
Medical Oncology, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Multidisciplinary treatment and translational research for kidney cancer, bladder cancer, prostate cancer, other urological tumors, and malignant melanoma, with a focus on advanced cases.
Dr. Sheng is Deputy Director of the Kidney Cancer and Melanoma Department at Peking University Cancer Hospital. Dr. Sheng contributed to the 2013, 2015, 2017, 2019, and 2020 CSCO Kidney Cancer Guidelines. Research findings were included in NCCN and CSCO guidelines. Dr. Sheng has published in journals including J Clin Oncol and Clin Cancer Res.
Professional roles
- Member, Chinese Medical Association
- Director, Chinese Society of Clinical Oncology (CSCO)
- Standing Committee Member, CSCO Urothelial Carcinoma Expert Committee
- Secretary-General, CSCO Kidney Cancer Expert Committee
Name order: in Chinese the family name comes first (Sheng Xinan). Papers usually list the name as Xinan Sheng or Sheng X.
Selected publications
138 papers on PubMed matched by name and affiliation; 36 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int Urol Nephrol, 2026 (senior author): Stage-specific associations of HER2 overexpression with clinical and pathological features in bladder cancer: a systematic review and meta-analysis. PubMed 41876828
- Cancer Metastasis Rev, 2026 (senior author): HER2 assessment in urothelial carcinoma: standardization challenges and the path forward. PubMed 42390654
- BMC Med, 2026 (senior author): Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study. PubMed 42387482
- Chin J Cancer Res, 2026 (senior author): Breakthroughs in malignancy therapy: New advances and emerging trends in renal cell carcinoma. PubMed 42421901
- BMC Cancer, 2026 (senior author): Features of tumor microenvironment in HER2-positive urothelial carcinoma and its implications for immunotherapy resistance. PubMed 42151849
- Oncologist, 2026 (senior author): Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: a subgroup analysis of the phase II POLARIS-03 trial. PubMed 41701175
- JAMA Oncol, 2026 (first author): Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial. PubMed 41481311
- Urol Oncol, 2026 (senior author): Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy. PubMed 41456965
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion